Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
-
Upload
tucker-webb -
Category
Documents
-
view
54 -
download
1
description
Transcript of Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?
![Page 1: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/1.jpg)
Dyslipidemia Management Beyond Statins:
Will PCSK9 Inhibition Trigger a Revolution?
![Page 2: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/2.jpg)
Patient Presentation
![Page 3: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/3.jpg)
On Exam
![Page 4: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/4.jpg)
Patient Follow-Up8 Weeks
![Page 5: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/5.jpg)
Case Questions
![Page 6: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/6.jpg)
Estimated Frequency of Individuals With Familial
Hypercholesterolemia
![Page 7: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/7.jpg)
Problems in Identifying FH Patients
![Page 8: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/8.jpg)
Statin Myopathy is a Common Challenge in Lipid Management
![Page 9: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/9.jpg)
Statins and New-Onset Type 2 Diabetes
Facts and Clinical Implications
![Page 10: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/10.jpg)
Case Questions
![Page 11: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/11.jpg)
Therapy for Statin Intolerance
![Page 12: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/12.jpg)
ODYSSEY FH I + II Alirocumab Significantly Reduced LDL-C From Baseline
to Week 24 vs Placebo
![Page 13: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/13.jpg)
Safety Analysis (Pooled Data From FH I and FH II)
![Page 14: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/14.jpg)
ODYSSEY ComboAlirocumab Significantly Reduced LDL-C From Baseline
to Week 25 vs Ezetimibe
![Page 15: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/15.jpg)
ODYSSEY LONG TERMAlirocumab Maintained Consistent LDL-C Reduction
Over 52 Weeks
![Page 16: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/16.jpg)
Adverse Events of Special Interest
![Page 17: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/17.jpg)
Post-hoc Adjudicated Cardiovascular Events*
![Page 18: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/18.jpg)
Abbreviations
![Page 19: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/19.jpg)
Abbreviations (cont)
![Page 20: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/20.jpg)
Abbreviations (cont)
![Page 21: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/21.jpg)
References
![Page 22: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/22.jpg)
References (cont)
![Page 23: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/23.jpg)
References (cont)
![Page 24: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/24.jpg)
References (cont)
![Page 25: Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?](https://reader030.fdocuments.net/reader030/viewer/2022032605/56812b94550346895d8fb4f5/html5/thumbnails/25.jpg)
References (cont)